Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New hope in irresectable hepatoma?

J R Novell1, N I Markham, K E Hobbs

  • 1Academic Department of Surgery, Royal Free Hospital School of Medicine, London, U.K.

Hepato-Gastroenterology
|August 1, 1989
PubMed
Summary

Hepatocellular carcinoma (HCC) treatment remains challenging. Combining Lipiodol with chemotherapy agents like epirubicin shows promise in reducing tumor size and improving survival for unresectable HCC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergency oesophageal transection to control bleeding varices.

Journal of the Royal Society of Medicine·2010
Same author

I don't fancy cheiromancy.

Journal of the Royal Society of Medicine·2010
Same author

Drainage after cholecystectomy.

Annals of the Royal College of Surgeons of England·2009
Same author

Trends in colorectal cancer survival following the 2-week rule.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2007
Same author

A single common urgent pathway for all colorectal referrals reduces time to diagnosis and treatment.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2006
Same author

The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2006

Area of Science:

  • Hepatology
  • Oncology
  • Interventional Radiology

Background:

  • Primary hepatocellular carcinoma (HCC) is often unresectable with limited survival.
  • Current palliative treatments offer minimal survival benefits.
  • Novel therapeutic strategies are crucial for improving HCC patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of Lipiodol combined with epirubicin in treating unresectable HCC.
  • To assess the impact of this combination therapy on tumor size and patient survival.

Main Methods:

  • A pilot study was followed by treatment of 16 HCC patients.
  • The treatment involved a combination of Lipiodol and epirubicin.
  • Lipiodol, an oily radiopaque agent, was used for selective infusion.

Main Results:

  • The combination therapy demonstrated a reduction in tumor size.
  • Survival time appeared to improve with Lipiodol-based treatments.
  • Epirubicin showed enhanced activity against HCC compared to doxorubicin.

Conclusions:

  • Lipiodol combined with cytotoxic agents like epirubicin is a promising approach for unresectable HCC.
  • Further research into targeted therapies and novel drug delivery systems is warranted.
  • Exploring new chemical and targeted techniques is essential for advancing HCC treatment.

Related Experiment Videos